Therapy Standards in HER2-Positive Breast Cancer

Publisher： Karger

E-ISSN： 1661-3805|11|2|148-150

ISSN： 1661-3791

Source： Breast Care, Vol.11, Iss.2, 2016-04, pp. : 148-150

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 424-426

Karger

Access to resources Recommend Favorite

Anti-HER2 Therapy Beyond Second-Line for HER2- Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

By  

Breast Care, Vol. 11, Iss. 2, 2016-02 ,pp. : 133-138

Karger

Access to resources Recommend Favorite

HER2-Orientated Therapy in Early and Metastatic Breast Cancer

By  

Breast Care, Vol. 11, Iss. 6, 2016-12 ,pp. : 392-397

Karger

Access to resources Recommend Favorite

Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report

By  

Breast Care, Vol. 12, Iss. 1, 2017-02 ,pp. : 45-47

Karger

Access to resources Recommend Favorite

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 168-171

Karger

Access to resources Recommend Favorite